[Possibilities of the use of moxonidine in the treatment of arterial hypertension in patients with metabolic syndrome and diabetes].
In pathogenesis of arterial hypertension (AH) and metabolic syndrome (MS) important role plays activation of sympathetic part of vegetative nervous system (VNS). Centrally acting antihypertensive drugs promote lowering of tone of its nuclei. Moxonidine belongs to this group of antihypertensive preparations. Mechanism of action of this drug, peculiarities of its pharmacokinetics are considered in this review. Data on antihypertensive efficacy of moxonidine, possibilities of combination therapy in AH are presented. Literature data on effect of therapy with moxonidine on carbohydrate metabolism, sensitivity of tissues to insulin are presented as well. Possible benefit from administration of this drug to patients with excessive body mass, MS, diabetes mellitus are shown. Data on organoprotective properties of moxonidine (effect on endothelial function, microalbuminuria) are analyzed.